ライフサイエンスコーパス: at age

1 hest percentage (100%) in infants (diagnosis at ages 0-12 months), followed by those diagnosed at age

2 ean scores on neurodevelopmental assessments at age 1 and 5 years and a higher prevalence of neurodev

3 st burden in children < 1 years old and peak at age 1 month.

4 , umami, and fat" (18% +/- 6%) clusters than at age 1 y (7% +/- 6%, 6% +/- 4%, and 11% +/- 6%, respec

5 quantified serum 25(OH)D in samples obtained at age 1 y from 306 participants in a cohort study in Sa

6 Serum 25(OH)D at age 1 y is inversely associated with childhood BMIZ,

7 whether serum 25-hydroxyvitamin D [25(OH)D] at age 1 y was related to metabolic health through adole

8 At age 1 y, the Structure and Control in Parent Feeding

9 -based sample of 5276 children was recruited at age 1 year and followed up at age 6 years.

10 valence of PV2 antibodies was 87/368 (23.6%) at age 1-7 months, 27/471 (5.7%) at 8-15 months, and 19/

11 evaluated for SDH at baseline (neonates) and at ages 1 and 2 years.

12 ric MRI for brain segmentation was performed at ages 1 and 2 years.

13 mplete twin pairs with information on height at ages 1 to 69 years and on parental education were poo

14 nary phthalate metabolites from 288 children at ages 1, 2, or 3 years (680 observations).

15 o treatment differences for acetabular index at age 10 months (p = 0.82) and walking age (p = 0.35).

16 k analyses for NRM, dichotomizing the cohort at age 10 years or younger and using each biomarker medi

17 At age 10 years, depressive symptoms were higher in sexu

18 mal weight more often reported that, already at age 10 years, their body size was below average or av

19 l depressive symptoms and child neuroimaging at age 10.

20 ight birth cohort (IOWBC) with DNAm in blood at ages 10 and 18 years (n = 124 females, 151 males) wer

21 was cost-effective in 41% of simulations and at ages 10 and 20 in 59% of simulations.

22 n of the aorta for IA and suggests screening at ages 10 and 20 or at 10, 20, and 30 years would exten

23 s was cost-effective compared with screening at ages 10 and 20 years (incremental cost-effectiveness

24 Screening at ages 10, 20, and 30 years led to 978 prophylactic tre

25 Screening at ages 10, 20, and 30 years was cost-effective compared

26 robabilistic sensitivity analysis, screening at ages 10, 20, and 30 years was cost-effective in 41% o

27 of whom 564 (57%) had received lead testing at age 11 years (302 [54%] male) (median follow-up, 34 [

28 A thin subfoveal choroid at age 11 years did not predict axial eye elongation and

29 Mean blood lead level at age 11 years was 10.99 (SD, 4.63) mug/dL.

30 A longer eye at age 11 years was associated with greater subsequent a

31 Childhood blood lead levels measured at age 11 years.

32 istance, beta-cell function, and adiponectin at age 11.5 years.

33 istance, beta-cell function, and adiponectin at age 11.5 years.

34 s investigated whether psychotic experiences at ages 11-12 predicted a psychiatric diagnosis or treat

35 al adversities and IQ, psychotic experiences at ages 11-12 predicted receiving a psychiatric diagnosi

36 ction in exposed offspring and juvenile mice at age 12 and 14 days, respectively.

37 itive composite scores according to exposure at age 12 and 24 months (p=0.19 and 0.24, respectively,

38 spective review comparing patients diagnosed at age 12 months or less (V-EoE, n = 57) and age 14 to 1

39 ly Learning (MSEL) cognitive composite score at age 12 months, 24 months, and 48 months; and the ment

40 For girls initiating vaccination at age 12-14 years and 15-16 years, 1-dose vaccine effec

41 structured Psychosis-Like Symptoms Interview at ages 12, 18, and 24 (N=7,900 with any data).

42 At ages 12-35 months, a PCV13 schedule containing two pr

43 otection against PCV13-serotype colonization at ages 13-24 months and 25-59 months, respectively.

44 f vaccine-serotype pneumococcal colonization at ages 13-24 months.

45 At age 14 mo, behavioral inhibition was assessed using a

46 The combined effect of sex on hip shape at age 14 reflected flatter femoral head and smaller les

47 ooster at age 22 weeks; group B received IPV at age 14 weeks and fIPV booster at age 22 weeks; group

48 to one of four groups: group A received IPV at age 14 weeks and IPV booster at age 22 weeks; group B

49 rences in proximal femur shape, particularly at age 14 were largely independent of body size, however

50 whole-brain analyses on structural MRI data at age 14 years, predicting change in neuroticism over t

51 ual minority versus heterosexual adolescents at age 14 years.

52 298 healthy adolescents were assessed at age 14- and 19-years using fMRI while performing a fa

53 e available for 4,428 and 4,369 participants at ages 14 and 18 years, respectively.

54 Subjects received a structural MRI scan at ages 14 and 19.

55 y), intakes of 38 food groups were estimated at ages 14, 17, 20 and 22 y in 1414 participants using e

56 fractive error and ocular biometric measures at age 15 years from 1613children.

57 HIV-free life expectancy at age 15 years improved significantly during the study

58 om their first inpatient psychiatric episode at age 15 years or older.

59 At age 15 years, no adverse associations with lung funct

60 ate an association with AXL and RCC measured at age 15 years.

61 n and with increased risk of incident myopia at age 16 years.

62 ted with childhood BMIZ, percentage body fat at age 16/17 y, and a MetS score at age 16/17 y.

63 MetS score (95% CI: -0.05, -0.01; P = 0.01) at age 16/17 y, through inverse associations with waist

64 ge body fat at age 16/17 y, and a MetS score at age 16/17 y.

65 lic syndrome (MetS) score and its components at age 16/17 y.

66 percentage fat and percentage lean body mass at age 16/17 y; and with a metabolic syndrome (MetS) sco

67 level models (self-harm in the previous year at ages 16 years and 21 years), and multinomial regressi

68 ttainment at 16 years (n = 9,959) and health at age 17 years (depression, obesity, harmful alcohol us

69 femoral pulse wave velocity [PWV]) measured at age 17 years.

70 a half-SD decrease in height-for-age z score at age 17, which is robust to several statistical checks

71 ewer-rated measures of psychotic experiences at age 18 (PPVs, 2.9% and 10.0%, respectively), was impr

72 The PPV of an at-risk mental state at age 18 predicting incident disorder at ages 18-24 was

73 echsler Adult Intelligence Scale was applied at age 18 y, and primary school completion was recorded.

74 he summary RR per 5 kg/m(2) increment in BMI at age 18 years was 1.17 (95% CI 1.01-1.36, I(2) = 26%,

75 Higher BMI in middle age, BMI at age 18 years, and waist circumference were associated

76 y peaked: rare or no misuse at any age, peak at age 18 years, peak at ages 19-20 years, peak at age 2

77 At age 18, smaller lesser trochanter and femoral neck wi

78 e children had low-positive anti-HCV results at age 18-24 months that were negative upon re-testing a

79 weight-for-length Z scores) and development at age 18-30 months.

80 mples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/

81 This study examined associations of CVH at ages 18 to 30 years with premature CVD and mortality.

82 state at age 18 predicting incident disorder at ages 18-24 was 21.1% (95% CI=6.1, 45.6) (sensitivity,

83 ged 14 years and from a subsample reassessed at age 19 years (n = 714).

84 The high PLEs group at age 19 years exhibited an enhanced response in right

85 eralized anxiety, and hyperactivity symptoms at age 19.

86 were assessed with the CAPE-42 questionnaire at age 19.

87 isuse at any age, peak at age 18 years, peak at ages 19-20 years, peak at age 23-24 years, and peak a

88 roups, whereas marked increases were evident at age 2 and 4(+) years only in Confirmed and Serologic

89 urves of 0.84 at age 3 to 15 months and 0.87 at age 2 to 3 years.

90 cohort were more varied and intense in taste at age 2 y than at 1 y, reaching a level similar to that

91 At age 2 y, children had higher energy intakes from the

92 obtained from the "neutral" cluster, whereas at age 2 y, this was 42% +/- 8%.

93 ent asthma, we saw the strongest association at age 2 years (adjOR = 1.22, 95% CI: 1.17-1.28), for sn

94 The primary outcome was eczema at age 2 years (defined by UK working party criteria) wi

95 developmental scores and gray matter volumes at age 2 years did not differ between asymptomatic neona

96 At age 2 years, eczema was present in 139 (23%) of 598 i

97 diagnosis of perinatally-acquired infection at age 2-6 months and could aid HCV surveillance given t

98 ly-exposed infants underwent HCV-RNA testing at age 2-6 months.

99 lly-exposed infants tested by HCV-RNA RT-PCR at age 2-6 months.

100 rn Israel, where children should receive PCV at ages 2 months, 4 months, and 12 months (2 primary [p]

101 Caries rates at ages 2 y (n = 535) and 3 y (n = 721) were 17.8% and 4

102 a/wheeze in age 0-8 years and current asthma at ages 2, 3, 4, 5 and 6 years.

103 ly larger ranges between reproductive states at age 20, by age 50, males were travelling 2.0 times fa

104 in Huntersville, NC, were diagnosed with UM at ages 20, 22, 24, 30, and 31.

105 ost at ages 55-69; homicide contributed most at ages 20-29.

106 CMVI passed the HS but was confirmed with HL at age 21 days.

107 e self-harm with and without suicidal intent at age 21 years).

108 IPV at 6 weeks and 14 weeks and fIPV booster at age 22 weeks.

109 received IPV at age 6 weeks and fIPV booster at age 22 weeks; and group D received fIPV at 6 weeks an

110 received IPV at age 14 weeks and IPV booster at age 22 weeks; group B received IPV at age 14 weeks an

111 eceived IPV at age 14 weeks and fIPV booster at age 22 weeks; group C received IPV at age 6 weeks and

112 The proportion of asthmatic patients at age 23 to 24 years differed between phenotypes, where

113 age 18 years, peak at ages 19-20 years, peak at age 23-24 years, and peak at ages 27-28 years.

114 Prediction of current psychotic disorder at age 24 (N=47, 1.2%), by both self-report and intervie

115 Of 3,866 participants interviewed at age 24, 313 (8.1%, 95% CI=7.2, 9.0) had a definite ps

116 Between 2010 and 2017, life expectancy at age 25 significantly declined among white and black n

117 In contrast, life expectancy at age 25 significantly increased among the college-educ

118 held back the increase of US life expectancy at age 25 y by 1.14 y in women and men, between 2010 and

119 s-sectional study, estimated life expectancy at age 25 years declined overall between 2010 and 2017;

120 Compared with no screening, starting at age 25 years, annual mammography with MRI averted the

121 increased from 42.7% and 16.7% respectively at age 25 years, to 83.7% and 81.1% at age 65 years.

122 al MRI with or without mammography, starting at age 25, 30, or 35 years.

123 Early initiation (at ages 25 to 30 years) of annual breast cancer screenin

124 g were completed in a subset of participants at age 26.

125 oning with friends and family (beta = -0.23) at age 26.

126 infant tptef/te reduced HRCT airway caliber at age 26.Conclusions: These findings underscore the lon

127 -20 years, peak at age 23-24 years, and peak at ages 27-28 years.

128 ed with isoform 1 via intrajugular injection at age 28-30 days exhibited significant behavioural impr

129 children's sense of fairness emerges already at age 3 in (and only in) the context of collaborative a

130 ned), PFNA and PFDA were associated with BF% at age 3 months (for 1-ng/mL PFDA, beta = 0.40; 95% CI:

131 At age 3 months, compared to controls, neopterin was red

132 patients with area under the curves of 0.84 at age 3 to 15 months and 0.87 at age 2 to 3 years.

133 rs; samples from 293 children were collected at age 3 to 15 months and 2 to 3 and 4(+) years.

134 At age 3 to 15 months, esIgE profiles were similar among

135 as significantly lower in the Tolerant group at age 3 to 15 months, increased in Confirmed and Serolo

136 ow risk group and three high-risk groups who at age 3 were developing (i) typically, (ii) atypically

137 total of 281(84%) children had complete data at age 3 years and were used to test the MAAS APT.

138 ASD-related social behavior was assessed at age 3 years using Social Responsiveness Scale (SRS-2)

139 microbiome and ASD-related social behaviors at age 3 years.

140 over 80% of the variance in nonverbal skills at age 3 years.

141 Nasal swab samples were collected at age 3, 6, 12, 18, 24, and 36 months and screened for

142 tivity Disorder and Mental Development Index at age 3.

143 Reductions in permeability and inflammation at ages 3 and 14 months suggest that the interventions p

144 the Strength and Difficulties Questionnaire at ages 3, 5, and 8 years, from which trajectories of an

145 and Allergy Study (MAAS) attended follow-up at ages 3, 8 and 11 years.

146 come was a parental report of child fracture at ages 3-10 years.

147 20 common tumour types diagnosed in 2008-17 at age 30 years and older from Public Health England.

148 justed life-year gained, screening beginning at age 30 years was preferred.

149 Nearly half occurred at ages 30-69 years and over a quarter in children < 15

150 ate adjusted rate ratios (RRs) for mortality at ages 30-69 years, comparing never-smokers with curren

151 ultrasound during the last follow-up (2011) at ages 34-49 years.

152 on carriers with hereditary pancreatitis and at age 35 years in the setting of Peutz-Jeghers syndrome

153 Cervical screening involved HPV testing at age 35 years, or at ages 35 years and 45 years, with

154 ing involved HPV testing at age 35 years, or at ages 35 years and 45 years, with scale-up to 45% cove

155 olved HPV testing once or twice per lifetime at ages 35 years and 45 years, with uptake increasing fr

156 te (45% versus 26.2%), older (25% versus 19% at ages 35-44), male (94% versus 81%), and not reside in

157 gher maternal education levels, and wheezing at age 36-72 months.

158 ood pressure measurements had been collected at ages 36, 43, 53, 60-64, and 69 years.

159 %) and 67.7% (-1962.9-100.0%), respectively, at ages 36-59 months.

160 ped memory impairment after a cardiac arrest at age 39.

161 equential ophthalmic examinations, beginning at age 4 to 6 weeks, to monitor the incidence and course

162 Child wheeze/asthma outcomes ascertained at age 4 to 6 years included ever physician-diagnosed as

163 for 173 uninfected and 106 infected infants at age 4 years (range 1 to 8 years).

164 for 173 uninfected and 106 infected infants at age 4 years (range, 1-8 years).

165 included 219 case patients and 417 controls at age 4 years and 228 case patients and 593 controls at

166 017) who underwent anthropometric evaluation at age 4 years and in at least 1 of the subsequent follo

167 At age 4(+) years, 38% of children were Tolerant or 14%

168 to 3-year samples can predict allergy status at age 4(+) years.

169 specific IgE is predictive of allergy status at age 4(+) years.

170 The end point was allergy status at age 4(+) years; samples from 293 children were collec

171 Their children had diffusion MRI at age 4.1 +/- 0.8 years, and children's behavior was as

172 sensitization(OR [95% CI] = 2.00 [1.04:3.86] at age 4; 2.35 [1.20:4.63] at age 7).

173 Blood samples drawn at ages 4 to 6 (n = 5989), 8 to 10 (n = 6603), and 15 to

174 At ages 4-11 months, two PCV13 doses provided 98.9% (-30

175 mammography before age 50 years, commencing at age 40 or 41 years, was associated with a relative re

176 Screening should be initiated at age 40 years in CKDN2A and PRSS1 mutation carriers wi

177 Screening starting at age 40 years or 10 years before the youngest PCA diag

178 Participants with glaucoma entered the model at age 40 years with a mean deviation in the better-seei

179 Beginning at an initial glaucoma diagnosis at age 40 years, patients proceeded to single-eye blindn

180 reening for Alzheimer-type dementia starting at age 40 years.

181 stimate the effect of mammographic screening at ages 40-48 years on breast cancer mortality.

182 te and relative differences in CVD mortality at ages 40-69 years between countries attributable to th

183 Men with diabetes reached 0.44% risk at age 45 (5 years earlier than the recommended age of s

184 associated with a 2.07-point lower IQ score at age 45 years (95% CI, -3.39 to -0.74; P = .002) and a

185 Structural brain integrity at age 45 years assessed via MRI (primary outcomes): gra

186 Cognitive function at age 45 years was assessed objectively via the Wechsle

187 f 1037 original participants, 997 were alive at age 45 years, of whom 564 (57%) had received lead tes

188 is of a hazard ratio of 1.25 per 5 BMI units at age 45 years, we estimated that 28% of US pancreatic

189 ars older (95% CI, 0.02-1.51 years; P = .05) at age 45 years.

190 aphy (CT) in 6,619 healthy adults, recruited at age 45-84 y without cardiovascular disease (CVD), ove

191 ltidisciplinary Health and Development Study at age 45.

192 At age 46 years, average annual rates of change in BMI,

193 had ES-HCM (EF 39 +/- 9%; range 12% to 49%) at age 48 +/- 15 years.

194 of the disease, proceeded to transplantation at age 49 with a 12/12 human leukocyte antigen-matched u

195 related to an adjusted 0.11 units lower BMIZ at age 5 y (95% CI: -0.20, -0.03; P = 0.01) and a 0.09 u

196 nfancy and childhood were associated with IQ at age 5 y in term-born children using path analysis.

197 position and markers of cardiometabolic risk at age 5 y.

198 osts, with interventions to reduce mortality at age 5-69 years from non-communicable disease and inju

199 Anthropometry was performed at ages 5, 10, and 16/17 y.

200 ancy 25(OH)D with BMI-for-age z-score (BMIZ) at ages 5, 10, and 16/17 y; with percentage fat and perc

201 hest in participants who had started smoking at ages 5-9 years (RR 2.51, 95% CI 2.21-2.85), followed

202 R for having all versus no healthy behaviors at age 50 being 0.28 (95% CI 0.15-0.52; p < 0.001).

203 Each healthy behavior at age 50 was associated with lower risk of incident fra

204 and an FEV(1)-to-forced vital capacity ratio at age 50 years (-3.36% [95% CI = -5.47 to -1.24] and -1

205 stical models for completed cohort fertility at age 50 years (CCF50).

206 al health summary scores of the participants at age 50 years from the 12-item Short-Form Survey, adju

207 proxy, whereby breast cancer cases or deaths at age 50 years or older were regarded as postmenopausal

208 eening in high-risk individuals should begin at age 50 years, or 10 years younger than the initial ag

209 930 individuals underwent spirometry testing at age 50 years.

210 mined the association between social contact at age 50, 60, and 70 years and subsequent incident deme

211 egetables at least twice a day-were measured at age 50, and change in behaviors was measured between

212 Our findings suggest that healthy behaviors at age 50, as well as improvements in behaviors over mid

213 amined the associations of healthy behaviors at age 50, singly and in combination, as well as 10-year

214 tacks, should be screened for HCC, beginning at age 50.

215 Official CRC screening starts at age 50.

216 cohort of 81 735 patients diagnosed with OSA at ages 50 to 90 years was identified from medical recor

217 st at ages 55-69, and unintentional injuries at ages 50-59.

218 Patient 1 proceeded to transplantation at age 53 with a haplo-identical sibling donor.

219 Heart disease and cancer contributed most at ages 55-69, and unintentional injuries at ages 50-59.

220 Heart disease and cancer contributed most at ages 55-69; homicide contributed most at ages 20-29.

221 vestigate changes in structural connectivity at age 6 and 8 years in children with and without PME.

222 ooster at age 22 weeks; group C received IPV at age 6 weeks and fIPV booster at age 22 weeks; and gro

223 r early infant HIV diagnosis with POC assays at age 6 weeks in Zimbabwe.

224 n upper airway mucosal cells and assessed AR at age 6 years in children in the Copenhagen Prospective

225 microbiota richness at 1 week on risk for AR at age 6 years was mediated in part by the epigenetic si

226 ethylated CpGs in upper airway mucosal cells at age 6 years, 792 of which formed 3 modules of correla

227 eek (richness P = .0079) in children with AR at age 6 years, and reduced diversity at 1 week was also

228 sted for sex, birth year, state of residence at age 6 years, and year of study enrollment.

229 At age 6 years, challenge-confirmed tree nut allergy pre

230 ecurrent wheeze progression to active asthma at age 6 years.

231 enge-confirmed tree nut allergy was assessed at age 6 years.

232 was recruited at age 1 year and followed up at age 6 years.

233 A follow-up assessment at age 6-10 years of a multicentre European birth cohort

234 and is recommended to infants as oral doses at ages 6 and 10 weeks.

235 ants and their mothers attended study visits at ages 6 weeks (for enrolment and randomisation), 10 we

236 ) in July 2013 using a 3-dose primary series at ages 6, 10, and 14 weeks with no booster.

237 to identify bacterial taxa in fecal samples at ages 6, 12, 18, and 24 months (N = 928).

238 peptide), interleukin (IL)-6, and E-selectin at age 60 to 64 years with performance at age 69 years,

239 t, and body mass index; then for performance at age 60 to 64 years.

240 More frequent social contact at age 60 years was associated with lower dementia risk

241 V) structure and function) measures recorded at age 60-64 yrs in a British birth cohort study.

242 0, 1.27-1.54; p<0.0001), but were attenuated at age 60-69 years, with no significant association obse

243 the highest incidence rates were registered at age 60-69 years.

244 lied to the sharp change in vaccination rate at age 65 years that resulted from an age-based vaccinat

245 ciated with poor or fair self-related health at age 65 years, but it was associated with the risk of

246 ectively at age 25 years, to 83.7% and 81.1% at age 65 years.

247 es (OR = 0.86, 95% CI: 0.59, 1.25; P = 0.42) at age 65 years.

248 ties (OR 0.86, 95% CI: 0.59, 1.25; P = 0.43) at age 65.

249 ectin at age 60 to 64 years with performance at age 69 years, adjusting for sex, height, and body mas

250 or without intraocular lens (IOL) placement at age 7 to 24 months with 5 years of postsurgical follo

251 A break point at age 7 years was set for the whole cohort and for SMA

252 2.00 [1.04:3.86] at age 4; 2.35 [1.20:4.63] at age 7).

253 rs, with no significant association observed at age 70 years and older.

254 among never users (estimated risk difference at age 70 years, 0.09% [95% CI, -0.02% to 0.19%]; estima

255 predict variation in cognitive ability level at age 70, and cognitive change from age 70 to age 79, i

256 sociated with the level of cognitive ability at age-70 baseline (range of standardized beta-values =

257 ut mice weighed 21% more than wild-type mice at age 8 weeks and a higher proportion developed fatal s

258 years and 228 case patients and 593 controls at age 8 years from 3 birth cohorts, with replication an

259 At age 8 years, 1 mug/m(3) higher exposure during the fi

260 At age 8 years, FEV(1) /FVC was significantly lower and

261 Associations of parental overweight status at age 8 years, puberty, and age 30 years with offspring

262 but significant reductions in lung function at age 8 years.

263 tion to FEV(1)% predicted and FVC% predicted at ages 8 (n = 5,276) and 15 (n = 3,446) years using lin

264 lth.Objectives: To investigate lung function at ages 8 and 15 years in relation to air pollution expo

265 Girls were vaccinated at age 9 years (with a catch-up to age 14 years), assumi

266 three core scenarios: girls-only vaccination at age 9 years with catch-up for girls aged 10-14 years;

267 ty among individuals who first formed stones at age 9-14 years, whereas controls displayed no age-rel

268 lowed up over six recruitment sweeps to date at ages 9 months, 3 years, 5 years, 7 years, 11 years, a

269 dentition dental examinations were conducted at ages 9, 13, 17, and 23 as part of the Iowa Fluoride S

270 Saving lives at ages below life expectancy is the key to increasing b

271 of diagnosis with patients diagnosed with UC at age between 40 and 64 years (adult age, A-O).

272 age <=18 years was 0.41 (CI, 0.24-0.57) and at age >18 years was 0.82 (CI, 0.67-0.98).

273 % seropositive rate among 1057 persons hired at age >50 years, only 84.4% of approximately 10 000 HCP

274 ort studies-Introducing complementary solids at age >= 4 months vs <4 months was not associated with

275 lts, 226 received follow-up anti-HCV testing at age >=18 months, of whom 223 tested negative.

276 ceive the recommended anti-HCV antibody test at age >=18 months.

277 ked these criteria and had negative anti-HCV at age >=18 months.

278 repeat HCV-RNA testing or positive anti-HCV at age >=24 months; 2) uninfected children lacked these

279 phrenia and those with no psychotic disorder at age >=25 years.

280 es 0-12 months), followed by those diagnosed at ages >1-18 years (40.3%) and >18-25 years (22.2%).

281 t in the general population, exposure to TBI at age < 30 years was associated with a 4.4-fold higher

282 s, summer season, nonexclusive breastfeeding at age <3 months, and formal childcare attendance before

283 by detection of CMV-DNA in saliva and urine at age <3 weeks.

284 cohort of women diagnosed with breast cancer at age <= 40 years and enrolled patients between 2006 an

285 ember 2012 with invasive early breast cancer at age <= 40 years and harbored deleterious germline BRC

286 l protection against GWs in girls vaccinated at age <=16 years.

287 Subjects were stratified by ADPKD diagnosis at age <=18 (childhood diagnosis [CD]) or>18 (adulthood

288 effectiveness of at least 1 HPV vaccine dose at age <=18 years or >18 years was 59% and 18%, respecti

289 nts; aPR for those who initiated vaccination at age <=18 years was 0.41 (CI, 0.24-0.57) and at age >1

290 Among women who received their first dose at age <=18, estimated HPV vaccine effectiveness was hig

291 otection against PCV13-serotype colonization at ages <=12 months; 1 primary-series dose was not prote

292 yes of 714 children (317 boys) were examined at age (median (IQR)) 11.5 (0.6) years and 16.6 (0.3) ye

293 Case fatality ratios spanned 0.05% at ages of 5 to 17 years to 16.6% at ages of 85 years or

294 nned 0.05% at ages of 5 to 17 years to 16.6% at ages of 85 years or more.

295 anterior descending coronary artery ligation at age P1 or P7.

296 PS2APP mice lacking Trem2 (PS2APP;Trem2(ko)) at ages ranging from 4 to 22 months.

297 et for therapeutics and diagnostics directed at age-related macular degeneration.

298 d still residing in their respective country at age six (N(Sweden) = 2,535,191, N(Denmark) = 1,382,36

299 years at diagnosis) and survivors diagnosed at age younger than 15 years (matched on primary cancer

300 In the PSC-IBD group, diagnosis of IBD at age younger than 40 years was associated with greater